PMID- 34603020
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211005
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk 
      Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis.
PG  - 707271
LID - 10.3389/fphar.2021.707271 [doi]
LID - 707271
AB  - Background: The treatment for high-risk non-muscle-invasive bladder cancer 
      (NMIBC) remains highly debated for its high recurrence and progression risk. This 
      work aimed to verify the efficacy and toxicity of intra-arterial chemotherapy 
      (IAC) plus intravesical chemotherapy (IVC) in high-risk NMIBC. Methods: A 
      comprehensive online literature search was conducted in three databases to select 
      researches related to IAC + IVC for high-risk NMIBC. All data were analyzed using 
      the Review Manager software version 5.3. And we used the Cochrane Risk of Bias 
      tool to assessed the quality of these enrolled researches. Results: Seven 
      eligible original publications were enrolled in our studies with a total of 1,247 
      patients. Compared with the intravesical instillation, IAC + IVC therapy showed a 
      better therapeutic effect. The total odds ratio for tumor recurrence rate, tumor 
      progression rate, survival rate, and tumor-specific death rate was calculated as 
      0.51 (95% CI: 0.36-0.72; p < 0.05), 0.51 (95% CI: 0.36-0.72; p < 0.05), 1.75 (95% 
      CI: 1.09-2.81; p < 0.05), and 0.48 (95% CI: 0.28-0.84; p < 0.05), respectively. 
      In patients who received IAC, most of the adverse events (AEs)in the treatment 
      were Grade I and II. Conclusion: IAC + IVC regimen for high-risk NMIBC could 
      effectively reduce recurrence and progression and provide a better prognosis than 
      intravesical instillation. The adverse events of IAC were mild and acceptable.
CI  - Copyright (c) 2021 Cheng, Qiu, Chen, Zu, Liu, Li, Hu, Yi, He, Chen and Cui.
FAU - Cheng, Chunliang
AU  - Cheng C
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Qiu, Dongxu
AU  - Qiu D
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Chen, Jinbo
AU  - Chen J
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Zu, Xiongbing
AU  - Zu X
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Liu, Jinhui
AU  - Liu J
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Li, Huihuang
AU  - Li H
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Hu, Jiao
AU  - Hu J
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Yi, Zhenglin
AU  - Yi Z
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - He, Tongchen
AU  - He T
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Chen, Zhi
AU  - Chen Z
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Cui, Yu
AU  - Cui Y
AD  - Department of Urology, Xiangya Hospital, Central South University, Changsha, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20210916
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8481664
OTO - NOTNLM
OT  - high-risk non-muscle-invasive bladder cancer
OT  - intra-arterial chemotherapy
OT  - intravesical chemotherapy
OT  - progression
OT  - recurrence
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/05 06:00
MHDA- 2021/10/05 06:01
PMCR- 2021/09/16
CRDT- 2021/10/04 05:56
PHST- 2021/05/09 00:00 [received]
PHST- 2021/07/30 00:00 [accepted]
PHST- 2021/10/04 05:56 [entrez]
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2021/10/05 06:01 [medline]
PHST- 2021/09/16 00:00 [pmc-release]
AID - 707271 [pii]
AID - 10.3389/fphar.2021.707271 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Sep 16;12:707271. doi: 10.3389/fphar.2021.707271. 
      eCollection 2021.